📰 Global External News
Page 11 - Global External News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Global External. Real-time updates on events, politics, business and more.
January 31, 2022
Investegate announcements from INVENTIVA, Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiation
January 20, 2022
Daix (France), Long Island City (New York, United States), January 20, 2022 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small
January 20, 2022
Investegate announcements from INVENTIVA, Inventiva announces participation at several conferences in January and February 2022
December 16, 2021
Investegate announcements from INVENTIVA, Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference
December 16, 2021
Daix (France), Long Island City (New York), December 16, 2021 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule
December 15, 2021
Press release content from Business Wire. The AP news staff was not involved in its creation.
December 6, 2021
Investegate announcements from INVENTIVA, Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor
November 3, 2021
Investegate announcements from INVENTIVA, Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021  
October 27, 2021
The LEGEND trial is a proof-of-concept Phase IIa clinical trial to evaluate the safety and efficacy of lanifibranor in combination with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin
October 27, 2021
Investegate announcements from INVENTIVA, Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes